Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the current study was to investigate the safety and tolerability of
BI 1356 BS following administration of multiple rising oral doses of 1 mg, 2.5 mg, 5 mg, and
10 mg over 12 days in male patients with type 2 diabetes.